NewAmsterdam Pharma Company (NAMS) Stock Analysis & AI Equity Report
NewAmsterdam Pharma Company (NAMS) overview
NewAmsterdam Pharma Company (NAMS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 22.5m and operating profit of USD -226m; the year-end share price was 35.08 USD and market capitalisation was USD 4,013m. NewAmsterdam Pharma Company is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get NewAmsterdam Pharma Company's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About NewAmsterdam Pharma Company
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing obicetrapib, an oral non-statin CETP inhibitor for patients with elevated LDL cholesterol and cardiovascular risk. The European Commission authorized obicetrapib as Ubeslo and in combination with ezetimibe as Evlarco, with Menarini responsible for European commercialization. NewAmsterdam continues Phase 3 cardiovascular trials and a Phase 2b study in preclinical Alzheimer’s disease.
Generate the NewAmsterdam Pharma Company report
NewAmsterdam Pharma Company is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for NewAmsterdam Pharma Company and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on NewAmsterdam Pharma Company
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.